New Non-Small Cell Lung Cancer Findings from First Affiliated Hospital Discussed (Real-world Evidence of Advanced Non-small Cell Lung Carcinoma Treated With an Immune Checkpoint Inhibitor Plus Chemotherapy).

A study conducted at the First Affiliated Hospital in Shandong, China, examined the real-world outcomes of patients with advanced non-small cell lung cancer (NSCLC) who were treated with immune checkpoint inhibitor (ICI)-based regimens. The study found that patients with a PD-L1 tumor proportion score (TPS) of >= 50% had favorable progression-free survival (PFS) and overall survival (OS) when treated with ICIs plus chemotherapy. Additionally, the study identified other factors, such as clinical stage, previous systemic therapy, and metastases, that were associated with PFS and OS. These findings suggest that immunotherapy is an effective treatment strategy for advanced NSCLC, particularly in patients with a high PD-L1 TPS. [Extracted from the article]